• Polaryx Therapeutics activated the first site for its SOTERIA Phase 2 trial of PLX-200 at Boys Town National Research Hospital in Nebraska.
• The oral treatment will be evaluated for safety and clinical activity in children with four rare lysosomal storage disorders.
• The site can begin screening eligible participants ahead of first patient dosing; clinical results have not yet been presented.
• Five additional US sites are scheduled for activation by the end of the first quarter of 2027, bringing the total to six.
• Applications submitted in October 2026 seek authorization to conduct SOTERIA in the European Union and United Kingdom in the first quarter of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polaryx Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090830PRIMZONEFULLFEED9872054) on November 09, 2026, and is solely responsible for the information contained therein.